Hearing loss drug triggers improvements in phase 1/2 trials

09-Apr-2019
KEY POINTS FROM ARTICLE:

Frequency Therapeutics’ hearing loss drug treatment clears Phase 1/2 trials.
Some patients showed improvements in hearing range tests and word scores.
FX-322 is a cocktail of small-molecule drugs designed to activate the body’s healing abilities.
Triggers dormant cells within the ear to grow fine hairs which can be damaged over time.
These hairs sense and translate sound waves into brain signals.
Plans to launch a phase 2a study before the end of the year.
There are currently no treatments to restore hearing for sensorineural hearing loss sufferers.
Small-molecule-driven platform may address numerous degenerative diseases.

Restoring hearing and vision would make many people's lives significantly easier
Read full article on FierceBiotech website
More Regenerative Medicine information, news and resources